RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase …
R Dummer, P Queirolo, AMA Guijarro, Y Hu… - The Lancet …, 2022 - thelancet.com
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
R Dummer, P Queirolo, PG Duhard, Y Hu… - The Lancet …, 2023 - thelancet.com
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Background Dabrafenib plus trametinib improves clinical outcomes in BRAF V600-mutant
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases
AM Di Giacomo, V Chiarion-Sileni, M Del Vecchio… - Clinical Cancer …, 2021 - AACR
Purpose: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series
K Holbrook, J Lutzky, MA Davies, JM Davis, IC Glitza… - Cancer, 2020 - Wiley Online Library
Background Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies
Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies
S Sloot, YA Chen, X Zhao, JL Weber, JJ Benedict… - Cancer, 2018 - Wiley Online Library
BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open …
HA Tawbi, PA Forsyth, FS Hodi, AP Algazi… - The lancet …, 2021 - thelancet.com
Background Combination nivolumab plus ipilimumab was efficacious in patients with
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …
Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.
HM Kluger, SB Goldberg, M Sznol, J Tsiouris… - 2015 - ascopubs.org
9009 Background: Brain metastases (BrMs) develop in 40% of metastatic melanoma (MM)
patients (pts). Untreated BrMs exclude from most clinical trials. In prior trials, treatment of MM …
patients (pts). Untreated BrMs exclude from most clinical trials. In prior trials, treatment of MM …
[HTML][HTML] Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
PA Ascierto, E Simeone, D Giannarelli… - Journal of translational …, 2012 - Springer
Background Ipilimumab and vemurafenib have both been shown to improve survival in
phase III trials of patients with metastatic melanoma. Although vemurafenib is associated …
phase III trials of patients with metastatic melanoma. Although vemurafenib is associated …